Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06623734
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-30
Brief Title:
Liver Cancer Investigation for Prognosis Study
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Liver CAncer PRognosis InvEstigation Study Liver-CARE
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This prospective cohort study is designed to explore the role of environmental clinical and genetic risk factors in the progression and prognosis of primary liver cancer PLC We will recruit 5000 patients with newly diagnosed previously untreated PLC The eligible patients will be asked to complete a baseline survey at the time of initial admission and be followed up every 3 to 6 months after discharge
Detailed Description:
Primary liver cancer PLC is highly malignant and is particularly prevalent in China Multiple factors are involved in the development and progression of PLC Several large-scale prospective cohort studies have been established to identify environmental and genetic risk factors for the development of PLC in the general population However few cohort studies have focused on determining risk factors beyond clinical prognostic factors for the progression of PLC in patients with PLC Therefore we will conduct a prospective cohort study to examine the role of environmental clinical and genetic risk factors in the progression and prognosis of PLC We plan to recruit 5000 patients with newly diagnosed previously untreated PLC A baseline survey will be conducted at the time of initial admission with follow-up at 3 and 6 months after discharge for all patients and thereafter every 3 months for patients treated with interventional therapy and every 6 months for patients receiving surgery and other therapies We will collect information on patients demographics characteristics clinical diagnosis and treatment lifestyle nutritional status psychological and mental status quality of life anthropometric data body composition routine laboratory tests and examinations and disease progression through structured questionnaires physical examinations and medical record reviews Deaths will be ascertained through medical records death certificates and next-of-kin Additionally we will collect blood urine stool and liver tissue samples
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None